SOUTH SAN FRANCISCO, Calif., May 29, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Jefferies 2013 Global Healthcare Conference on Wednesday, June 5 at 4:30 p.m. ET. Jeffrey S. Farrow, Chief Financial Officer will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm . About Hyperion Therapeutics Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, Ravicti™(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. For more information, please visit www.hyperiontx.com .
CONTACT: Sylvia Wheeler, Investor Relations (650) 794-7834 email@example.com